Podcast- Hypocalcemia in Children
Learning Objectives
By the end of this course, the learners should be able to:
- Describe calcium homeostasis
- Define hypercalcemia and its significance in children
- Review etiologies, evaluations, and management
- Contrast treatment approach in acute symptomatic vs. chronic, asymptomatic hypocalcemia
Intended Audience:
This online course is designed for pediatricians, family physicians, endocrinologists, pediatric endocrinologists, emergency physicians, and ICU doctors.
Abstract:
In this episode, Dr. Eyal Ben-Isaac interviews Dr. Anna Ryabets-Lienhard, pediatric endocrinologist and Medical Director of the Metabolic Bone and Mineral Disorders Program at Children’s Hospital Los Angeles, about hypocalcemia in children. They review the physiology of calcium homeostasis, the diverse causes and clinical manifestations of hypocalcemia across different age groups, and a practical approach to diagnosis and management. The discussion highlights the roles of parathyroid hormone, vitamin D, magnesium, and phosphate, while providing clinical pearls on recognizing endocrine emergencies, interpreting laboratory findings, and distinguishing acute symptomatic hypocalcemia from chronic conditions to guide timely and effective treatment.
Assessment and Earning CME Credit:
This course in English is not CME-accredited. However, it provides valuable educational content that can enhance your knowledge and skills in the subject matter. To receive CME credit for this course in Armenia, you must take the course in Armenian and complete the post-course quiz. You have three chances to achieve a passing score of 70%. Once you pass the quiz, we will send your information to the Armenian Ministry of Health for credits.
Anna Ryabets-Lienhard, DO
Anna Ryabets-Lienhard, D.O. is the Medical Director of Metabolic Bone and Mineral Disorders Program at the Division of Endocrinology, Diabetes, and Metabolism, Children’s Hospital Los Angeles (CHLA), and an Assistant Professor of Clinical Pediatrics, Keck School of Medicine of the University of Southern California. She is a board-certified pediatric endocrinologist and an attending physician at CHLA. Dr. Ryabets-Lienhard completed her pediatric residency and pediatric endocrinology fellowship at CHLA. Her research and clinical focus are on primary and secondary pediatric osteoporosis, such as Osteogenesis Imperfecta and Glucocorticoid-Induced Osteoporosis, as well as rickets and mineral disorders. She is a site principal investigator on multiple clinical trials and a co-principal investigator on a multidisciplinary multisite study of metabolic and orthopedic outcomes of patients with congenital forms of rickets. Dr. Ryabets-Lienhardis on the Board of Directors for the Human Growth Foundation and co-chair of the Drugs and Therapeutics Committee of the Pediatric Endocrine Society, USA.
